<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738162</url>
  </required_header>
  <id_info>
    <org_study_id>UKM2013_0034</org_study_id>
    <secondary_id>2014-005669-54</secondary_id>
    <nct_id>NCT04738162</nct_id>
  </id_info>
  <brief_title>Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors</brief_title>
  <official_title>Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westfälische Wilhelms-Universität Münster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>photonamic GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Westfälische Wilhelms-Universität Münster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA&#xD;
      in children and adolescents with supratentorial brain tumors 80 patients will be&#xD;
      investigated.&#xD;
&#xD;
      Primary objective of the study is to determine the safety of 5-ALA for fluorescence-guided&#xD;
      resections in children and adolescents with supratentorial, intra-axial brain tumors.&#xD;
&#xD;
      Secondary objectives are&#xD;
&#xD;
        -  to determine whether fluorescent tissue truly signifies tumor (positive predictive&#xD;
           value) in various pediatric brain tumors&#xD;
&#xD;
        -  to determine the degree of tumor resection on early post-operative MRI&#xD;
&#xD;
        -  and to determine the pharmacokinetics of 5-ALA in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2007, 5-aminolevulinic acid (5-ALA) was approved in Europe by the European Medicines&#xD;
      Agency (EMA) (brand name: Gliolan®) for &quot;the visualization of malignant tissue during surgery&#xD;
      for malignant glioma (WHO III and IV) in adults.&quot; Similarly, approval for 5-ALA was granted&#xD;
      by the FDA in 2017 as an &quot;optical imaging agent indicated in patients with gliomas (suspected&#xD;
      World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the&#xD;
      visualization of malignant tissue during surgery&quot; (brand name: Gliolan®). Goal of the study&#xD;
      is to investigate if the use of 5-ALA is safe in children and get preliminary information on&#xD;
      the type of paediatric brain tumors which are suitable for fluorescence-guided resection with&#xD;
      5-ALA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of 5-ALA for fluorescence-guided resections in children and adolescents determined as incidence of adverse events of CTCAE grade III-V.</measure>
    <time_frame>up to 6 weeks after tumor resection</time_frame>
    <description>Incidence of adverse events of CTCAE grade III, IV or V (excluding chemotherapy-associated toxicities) during and after 5-ALA fluorescence-guided resections in children and adolescents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>True positive rate of fluorescence for indicating tumor</measure>
    <time_frame>Day 0: during the surgery</time_frame>
    <description>Biopsies will be taken during tumor resection. The true positive rate of 5 ALA induced fluorescence for three different tumor regions, i.e. the number of fluorescing tumor samples containing tumor cells divided by the number of all tumor samples from 1) the tumor bulk, 2) the border area and 3) the suspected infiltration zone. A stratification will be performed depending on whether surgery is for newly diagnosed or recurrent tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the percentage of patients with gros total resection and subtotal resection</measure>
    <time_frame>up to 72h after surgery</time_frame>
    <description>For every patient in whom a complete resection of enhancing tumor is expected a priori, it will be assessed whether there is residual contrast-enhancement or not on early post-operative MRI. The volume of contrast-enhancing tumor on early post-operative MRI (up to 72h after surgery) in cm3 will be determined. If the volume is &lt; 0.175cm3, the patient will be classified as &quot;gros total resection&quot;. If the volume is &gt;0.175cm3, the patient will be classified as &quot;subtotal resection&quot;. Percentage of patients for both groups will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of residual contrast-enhancing tumor with residual fluorescence after surgery</measure>
    <time_frame>Day 0: during the surgery</time_frame>
    <description>For both groups (patients with gros total and subtotal resection) the percentage of patients with residual fluorescence at end of surgery, as determined during the surgery by the operating surgeon (yes/no), will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of protoporphyrin IX (PPIX) in serum to analyse AUC (Area under the curve) of PPIX</measure>
    <time_frame>3-6 hours, 6-9 hours and 9-12 hours after surgery</time_frame>
    <description>The investigators aim to determine 5-ALA pharmacokinetics in children and adolescents from PPIX plasma levels in order to assess if the pharmacokinetics differ between adults and children. Pharmacokinetic data will be analyzed using population pharmacokinetic software approach using nonlinear-mixed effects modelling (NONMEM). In order to assess if the pharmacokinetics are similar, the area under the curve (AUC) for PPIX as a measure of 5-ALA exposure will be calculated. For this purpose protoporphyrin IX will be measured in serum 3 times within 12h after 5-ALA-administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of protoporphyrin IX (PPIX) in serum to determine interpolated maximum plasma concentration (Cmax) of PPIX.</measure>
    <time_frame>3-6 hours, 6-9 hours and 9-12 hours after surgery</time_frame>
    <description>Protoporphyrin IX will be measured in serum 3 times within 12h after 5-ALA-administration. Pharmacokinetic data will be analyzed using population pharmacokinetic software approach using nonlinear-mixed effects modelling (NONMEM). Using the model, interpolated maximum plasma concentration (Cmax) of PPIX will be determined for every patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Brain Tumor, Pediatric</condition>
  <arm_group>
    <arm_group_label>5-Aminolevulinic Acid (5-ALA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Aminolevulinic Acid Hydrochloride, Oral</intervention_name>
    <description>Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible</description>
    <arm_group_label>5-Aminolevulinic Acid (5-ALA)</arm_group_label>
    <other_name>Gliolan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 3 - &lt;18 years&#xD;
&#xD;
          -  First radiological diagnosis of intra-axial, supratentorial contrast-enhancing tumor&#xD;
             on MRI or recurrent supratentorial intra-axial brain tumor (malignant glioma,&#xD;
             astrocytoma, malignant ependymoma, atypical teratoid rhabdoid tumors (AT/RT),&#xD;
             Oligodendroglioma, etc.)&#xD;
&#xD;
          -  Resection is part of therapeutic strategy with an emphasis on neurological safety&#xD;
&#xD;
          -  Informed consent by the parents or guardians and if possible assent of the patient&#xD;
             after education of purpose and risks of study. Patients that are able to understand&#xD;
             should provide assent to participate in the trial&#xD;
&#xD;
          -  Female adolescents: not pregnant (pregnancy test required for adolescents of&#xD;
             child-bearing age) and not breast-feeding (for at least 24 hours after Gliolan&#xD;
             intake). Female patients of childbearing potential and male patients who are sexually&#xD;
             active must be practising a highly effective method of birth control up to 6 weeks&#xD;
             after the tumor operation consistent with local regulations regarding the use of birth&#xD;
             control methods for subjects participating in clinical trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Posterior fossa tumors&#xD;
&#xD;
          -  Extra-axial tumors such as craniopharyngioma&#xD;
&#xD;
          -  Germ cell tumor or entities precluding surgical resection&#xD;
&#xD;
          -  Acute or chronic porphyria&#xD;
&#xD;
          -  Hypersensitivity to 5-ALA or porphyrins&#xD;
&#xD;
          -  Renal insufficiency: serum creatinine &gt; 2x upper limit of normal (ULN)&#xD;
&#xD;
          -  Hepatic insufficiency: serum bilirubin &gt; 2x ULN, serum γ-glutamyl transferase &gt; 2,5 x&#xD;
             ULN, alanine transaminase (ALT) and aspartate transaminase (AST)&gt; 2,5 ULN&#xD;
&#xD;
          -  Blood clotting: INR (international normalized ratio) out of acceptable limits&#xD;
&#xD;
          -  Other malignant disease&#xD;
&#xD;
          -  Patients with pre-existing cardiovascular diseases&#xD;
&#xD;
          -  Co-administration with other potentially phototoxic substances (e.g. tetracyclines,&#xD;
             sulfonamides, fluoroquinolones, hypericin extracts)&#xD;
&#xD;
          -  Planned administration of potentially hepatotoxic substances within 24 hours after&#xD;
             5-ALA administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Stummer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Schwake, Dr.</last_name>
    <phone>+49 251 83</phone>
    <phone_ext>47484 /47472</phone_ext>
    <email>Michael.Schwake@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walter Stummer, Prof. Dr.</last_name>
    <phone>+49 251 83</phone>
    <phone_ext>47472</phone_ext>
    <email>Walter.Stummer@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Neurochirurgie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Dammann, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Philip Dammann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Pierscianek, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Klinik der Universität München (LMU)</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niklas Thon, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Niklas Thon, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogdana Suchorska, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster, Klinik für Neurochirurgie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schwake, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Walter Stummer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Schwake, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Klinik für Neurochirurgie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schumann, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Martin Schuhmann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Constantin Roder, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schwake M, Schipmann S, Müther M, Köchling M, Brentrup A, Stummer W. 5-ALA fluorescence-guided surgery in pediatric brain tumors-a systematic review. Acta Neurochir (Wien). 2019 Jun;161(6):1099-1108. doi: 10.1007/s00701-019-03898-1. Epub 2019 Apr 13.</citation>
    <PMID>30989383</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>5-ALA</keyword>
  <keyword>supratentorial</keyword>
  <keyword>intra-axial</keyword>
  <keyword>Fluorescence-guided resection</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

